Evidence map›Paper›PMID 40713679›Full record

ArticleWorld journal of surgical oncology2025

HER2 mutations in pulmonary adenocarcinoma presenting with ground-glass nodules.

Jiacheng Yin, Shuhua Huo, Zhencong Chen, Yu Shi, Qihai Sui, Qun Wang, Jiangjiang Xu, Wei Jiang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jiacheng Yin *Department of Thoracic Surgery, Zhongshan Hospital of Fudan University, No. 180, Fenglin Road, Shanghai, 200032, China.
Shuhua Huo *Department of Thoracic Surgery, The First Affiliated Hospital of Xinxiang Medical University, Henan, China.
Zhencong ChenDepartment of Thoracic Surgery, Zhongshan Hospital of Fudan University, No. 180, Fenglin Road, Shanghai, 200032, China.
Yu ShiDepartment of Thoracic Surgery, Zhongshan Hospital of Fudan University, No. 180, Fenglin Road, Shanghai, 200032, China.
Qihai SuiDepartment of Thoracic Surgery, Zhongshan Hospital of Fudan University, No. 180, Fenglin Road, Shanghai, 200032, China.
Qun WangDepartment of Thoracic Surgery, Zhongshan Hospital of Fudan University, No. 180, Fenglin Road, Shanghai, 200032, China.
Jiangjiang XuDepartment of Thoracic Surgery, Fuding Hospital, Fujian University of Traditional Chinese Medicine, Fuding, 355200, Fujian, China. virgilbetter@163.com.
Wei JiangDepartment of Thoracic Surgery, Zhongshan Hospital of Fudan University, No. 180, Fenglin Road, Shanghai, 200032, China. jiang.wei1@zs-hospital.sh.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHuman epidermal growth factor receptor 2 (HER2) mutations have been identified as oncogenic drivers and therapeutic targets in Non-small cell lung cancers (NSCLCs). The role of HER2 mutation in lung adenocarcinoma presented as sub-solid nodules (SSNs) have not been distinctly defined. This study comprehensively investigated the clinicopathological characteristics of HER2 mutation in patients with pulmonary SSNs.

methodsIn total, 717 patients with completely resected NSCLCs presented as SSNs were examined for HER2 mutation from January 2016 to December 2018. Age, sex, smoking history, radiologic features, operative procedure, pleural invasion, histologic subtypes and tumor-node-metastasis stage were collected. Kaplan-Meier method was used to estimate DFS, Log-rank test was used to compare the survival data. Logistic regression model was used to identify the predictors for HER2 mutation and the predictive nomogram was built.

resultsIn this study, 47(6.6%) SSNs carried HER2 mutations. HER2 mutations were more frequent in subjects with younger age (P < 0.001) and smaller tumor size (P < 0.001), and were prone to occur in AIS and MIA (P < 0.001). The 5- year DFS rates for HER2 mutation and HER2 wild-type groups were similar (P = 0.509). According to the logistic regression analysis, age and maximum tumor size were independent variables correlated with HER2 mutation. A predictive nomogram model was constructed with a concordance statistic of 0.79 (0.71-0.87).

conclusionsHER2 mutation was not uncommon in pulmonary SSNs. Younger age and smaller tumor size were associated with increased odds of HER2 mutation.

Indexed as

Adenocarcinoma of LungBiomarkers, TumorCarcinoma, Non-Small-Cell LungErb-b2 Receptor Tyrosine KinasesLung NeoplasmsMutationAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesHER2 mutationLung cancerSub-solid nodule

Identifiers

PMID40713679
PMCPMC12297846

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.